Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Disease Detection International

This article was originally published in The Gray Sheet

Executive Summary

Considering proposal by Irish firm Trinity Biotech to merge via a stock swap. DDI announced Jan. 17 that it had received a letter of intent from Trinity's board proposing a merger of the two companies. The proposal "contemplates an exchange of shares in which stockholders of Disease Detection International, other than Trinity, would receive American Depositary Receipts representing ordinary shares of Trinity," the release states. Trinity, which reportedly owns about 400,000 shares of DDI's common stock and all of the company's Series A preferred stock, holds a license to DDI's SeroCard diagnostic test for sexually transmitted and infectious diseases. Using the rapid test format of the SeroCard along with a saliva detection method obtained from Amsterdam-based Saliva Technologies, Trinity is developing a test to detect HIV-1 antibodies in saliva ("The Gray Sheet" April 26, 1993, I&W-4)

You may also be interested in...

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.

Deal Watch: Novo Nordisk, Fauna To Explore Hibernation To Treat Obesity

A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.

Scrip’s Rough Guide On The State Of RNAi

The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts